Good points. Thanks for clarifying. Hopefully we’ll get blinded paper soon and unblinded results this year. FDA approval should come on the heels of positive data. Then the cash flowing can begin.
I agree somewhat. We are about ripe with the data but I would like to see as many survivors past 3 years count. Although, we should only expect around 25% of the 75 remaining patients March-Nov enrolled to still be alive. ( About 19). We may need them for stat significance on 3 year survival. I expect data lock and unbinding to occur in the next couple months with spring refresh. How bout you Flip?
News 
Market Data 
Discover 
AI
